S
Sten Holmäng
Researcher at Sahlgrenska University Hospital
Publications - 86
Citations - 3673
Sten Holmäng is an academic researcher from Sahlgrenska University Hospital. The author has contributed to research in topics: Bladder cancer & Cystectomy. The author has an hindex of 29, co-authored 85 publications receiving 3332 citations. Previous affiliations of Sten Holmäng include Umeå University & University of Gothenburg.
Papers
More filters
Journal ArticleDOI
The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease
Robert S. Svatek,Brent K. Hollenbeck,Sten Holmäng,Richard K. Lee,Simon P. Kim,Arnulf Stenzl,Yair Lotan +6 more
TL;DR: Regardless of disease severity, improvements in the efficiency of bladder cancer care to limit unnecessary interventions and optimize effective cancer treatment can reduce overall health care costs.
Journal ArticleDOI
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
Richard Sylvester,Willem Oosterlinck,Sten Holmäng,Matthew R. Sydes,Alison Birtle,Sigurdur Gudjonsson,Cosimo De Nunzio,Kikuo Okamura,Eero Kaasinen,Eduardo Solsona,Bedeir Ali-El-Dein,Can Ali Tatar,Brant A. Inman,James N'Dow,Jorg R. Oddens,Marek Babjuk +15 more
TL;DR: A single instillation of chemotherapy immediately after resection reduces the risk of recurrence in non-muscle-invasive bladder cancer; however, it should not be given to patients at high risk of Recurrence due to its lack of efficacy in this subgroup.
Journal ArticleDOI
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.
Evanguelos Xylinas,Michael S. Kent,Luis A. Kluth,Luis A. Kluth,Armin Pycha,Evi Comploj,Robert S. Svatek,Yair Lotan,Quoc-Dien Trinh,Pierre I. Karakiewicz,Sten Holmäng,Douglas S. Scherr,Marc Zerbib,Andrew J. Vickers,S.F. Shariat,S.F. Shariat +15 more
TL;DR: The EORTC risk tables and the CUETO scoring system exhibit a poor discrimination for both disease recurrence and progression in NMIBC patients, which underline the need for improving the current predictive tools.
Journal ArticleDOI
Micropapillary bladder carcinoma: a clinicopathological study of 20 cases.
TL;DR: The light microscopic appearance, which is strikingly similar to ovarian papillary serous carcinoma, and immunohistochemical staining pattern lend some support to the theory that micropapillary bladder carcinoma is a variant of adenocarcinoma.
Journal ArticleDOI
Recurrence and progression in low grade papillary urothelial tumors
TL;DR: Long-term followup data on patients with World Health Organization grade I bladder tumors are reported to determine whether histopathological subgrouping as papillary neoplasm of low malignant potential and low grade papillary carcinoma is of clinical value, and to add valuable prognostic information.